Epirubicin

• CAT Number: I004109
• CAS Number: 56420-45-2
• Molecular Formula: C27H29NO11
• Molecular Weight: 543.52
• Purity: ≥95%
• Target: Apoptosis
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• InChI: InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
• InChIKey: AOJJSUZBOXZQNB-VTZDEGQISA-N
• SMILES: C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O

Epirubicin（Cat No.:I004109）is an anthracycline chemotherapy drug widely used to treat various cancers, including breast cancer, gastric cancer, and lymphoma. It works by intercalating into DNA and inhibiting topoisomerase II, leading to DNA damage, disrupted replication, and apoptosis in rapidly dividing cancer cells. Epirubicin also generates free radicals, further enhancing its cytotoxic effects. Its improved cardiotoxicity profile compared to other anthracyclines makes it a preferred option in many regimens. Epirubicin is extensively studied for its mechanisms of action, resistance development, and potential in combination cancer therapies.

Reference

[1]. Cersosimo, R.J. and W.K. Hong, Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol, 1986. 4(3): p. 425-39.

[2]. Ozkan, A. and K. Fiskin, Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44.

[3]. Bonadonna, G., et al., Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69.